Xstelos Holdings Inc. XTLS Company Overview Stock

New Post Public Reply Private Reply Replies (0) Message Board

Sep 18, 2013 at 4:06 PM

Xstelos Holdings Inc. XTLS Company Overview

Stock Message Board http://investorshangout.com/search?q=XTLS&...mp;yt1=Go!

Xstelos Holdings Inc. XTLS Current Price and Quotes
Last Price 1.30
Previous Close 1.30 Open 1.30
Daily Range 1.30 - 1.30 52wk Range 2.10 - 1.25
Volume 4,000 Dividend N/A
Average Vol (3m) 3,626 Yield N/A
Xstelos Holdings Inc. XTLS
Company Information

630 Fifth Avenue
Suite 2260
New York, NY 10020

Phone: 212-729-4962

Xstelos Holdings Inc. XTLS
Xstelos Holdings Inc. XTLS
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Jun 30, 2013 10-Q
CIK 0001540145
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data

SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 2007
Employees 7 a/o Jan 24, 2012
Company Officers/Contacts

Jonathan M. Couchman President, CEO
Company Directors

Jonathan M. Couchman Chairman
Eugene I. Davis
Adam W. Finerman
Service Providers

Auditor/Accountant
BDO USA, LLP
755 West Big Beaver
Suite 1900
Troy, MI, 48084
United States

Legal Counsel
Not Available
Investor Relations Firm
Not Available

Xstelos Holdings Inc. XTLS
XTLS Security Details

Share Structure

Market Value1 $31,545,539 a/o Sep 17, 2013
Shares Outstanding 24,265,799 a/o Aug 12, 2013
Float Not Available
Authorized Shares 35,000,000 a/o Apr 05, 2011
Par Value 0.01
Shareholders

Shareholders of Record 2,373 a/o Apr 01, 2013
Corporate Actions

Ex. Date Record Date Pay Date
Dividend (0.30) Dec 18, 2012 Dec 20, 2012 Dec 28, 2012
Short Selling Data

Short Interest 0 (-100%)
Aug 15, 2013
Significant Failures to Deliver No
Transfer Agent(s)

Securities Transfer Corp

Xstelos Holdings Inc. XTLS Recent News

Xstelos Holdings Inc. XTLS Financials
Period Ending Dec 31, 2012 Dec 31, 2011
Total Revenue 28,726 19,350
Cost of Revenue - -
Gross Profit 28,726 19,350
Operating Expenses

Research and Development - -
Sales, General and Admin. 6,352 7,053
Non-Recurring Items - -
Other 4,102 3,010
Operating Income 18,272 9,287
Income From Continuing Operations

Add'l Income/Expense Items 7,493 (2)
Earnings Before Interest and Tax 25,765 9,285
Interest Expense 10,433 8,678
Earnings Before Tax 15,332 607
Income Tax (19,671) (19,438)
Minority Interest 2,145 884
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations 35,003 20,045
Non Recurring Events

Discontinued Operations 1,145 1,365
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income 34,003 20,526
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders 34,003 20,526

XTLS Xstelos Holdings Inc. Research DD Guide

XTLS Xstelos Holdings Inc. Stock Message Board http://investorshangout.com/search?q=XTLS&...mp;yt0=Go!
XTLS Xstelos Holdings Inc. Stock Quote http://www.otcmarkets.com/stock/XTLS/quote
XTLS Xstelos Holdings Inc. Stock Chart http://www.otcmarkets.com/stock/XTLS/chart
XTLS Xstelos Holdings Inc. Company Info http://www.otcmarkets.com/stock/XTLS/company-info
XTLS Xstelos Holdings Inc. Recent News http://www.otcmarkets.com/stock/XTLS/news
XTLS Xstelos Holdings Inc. Financials http://www.otcmarkets.com/stock/XTLS/financials
XTLS Xstelos Holdings Inc. Filings and Disclosure http://www.otcmarkets.com/stock/XTLS/filings
XTLS Xstelos Holdings Inc. Short Sales http://www.otcmarkets.com/stock/XTLS/short-sales
XTLS Xstelos Holdings Inc. Insider Disclosure http://www.otcmarkets.com/stock/XTLS/insider-transactions
XTLS Xstelos Holdings Inc. Research Reports http://www.otcmarkets.com/stock/XTLS/research
XTLS Xstelos Holdings Inc. Summary http://finance.yahoo.com/q?s=XTLS
XTLS Xstelos Holdings Inc. Historical Prices http://finance.yahoo.com/q/hp?s=XTLS+Historical+Prices
XTLS Xstelos Holdings Inc. Interactive Chart http://finance.yahoo.com/echarts?s=XTLS
XTLS Xstelos Holdings Inc. Basic Chart http://finance.yahoo.com/q/bc?s=XTLS+Basic+Chart
XTLS Xstelos Holdings Inc. Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=XTLS+Basic+Tech.+Analysis
XTLS Xstelos Holdings Inc. Headlines http://finance.yahoo.com/q/h?s=XTLS+Headlines
XTLS Xstelos Holdings Inc. Press Releases http://finance.yahoo.com/q/p?s=XTLS+Press+Releases
XTLS Xstelos Holdings Inc. Company Profile http://finance.yahoo.com/q/pr?s=XTLS+Profile
XTLS Xstelos Holdings Inc. Key Statistics http://finance.yahoo.com/q/ks?s=XTLS+Key+Statistics
XTLS Xstelos Holdings Inc. Industry http://finance.yahoo.com/q/in?s=XTLS+Industry
XTLS Xstelos Holdings Inc. Major Holders http://finance.yahoo.com/q/mh?s=XTLS+Major+Holders
XTLS Xstelos Holdings Inc. Insider Transactions http://finance.yahoo.com/q/it?s=XTLS+Insider+Transactions
XTLS Xstelos Holdings Inc. Insider Roster http://finance.yahoo.com/q/ir?s=XTLS+Insider+Roster
XTLS Xstelos Holdings Inc. Income Statement http://finance.yahoo.com/q/is?s=XTLS
XTLS Xstelos Holdings Inc. Balance Sheet http://finance.yahoo.com/q/bs?s=XTLS
XTLS Xstelos Holdings Inc. Cash Flow http://finance.yahoo.com/q/cf?s=XTLS+Cash+Flow&annual
XTLS Xstelos Holdings Inc. Nasdaq http://www.nasdaq.com/symbol/XTLS
XTLS Xstelos Holdings Inc. Market Watch http://www.marketwatch.com/investing/stock/XTLS
XTLS Xstelos Holdings Inc. Bloomberg http://www.bloomberg.com/quote/XTLS:US
XTLS Xstelos Holdings Inc. Morningstar http://quotes.morningstar.com/stock/s?t=XTLS
XTLS Xstelos Holdings Inc. Bussinessweek http://investing.businessweek.com/research/st...icker=XTLS
XTLS Xstelos Holdings Inc. Barchart http://www.barchart.com/quotes/stocks/XTLS
XTLS Xstelos Holdings Inc. OTC Short Report http://otcshortreport.com/index.php?index=XTLS
XTLS Xstelos Holdings Inc. Investopedia http://www.investopedia.com/markets/stocks/XTLS/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...